Joyce M. Teng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Joyce M. Teng has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Amy L. O’bRian
1 shared publicationAnna K. Haemel
Departments of Dermatology and Pediatrics, University of Wisconsin School of Medicine and Public Health, 1 S Park St, Seventh Floor, Madison, WI 53715.
1 shared publication- Beth VanderWielen
Mayo Clinic
1 shared publication Chethana Chandrupatla Gottam
1 shared publicationGary P. Williams
1 shared publicationJack B. Longley
1 shared publication
Latest Publications
- 11 July 2012
- Published by Wiley in Pediatric Dermatology
- Vol. 29 (6) , 707-713
Dermatofibrosarcoma Protuberans in Children: an Update on the Diagnosis and Treatment
Abstract: Dermatofibrosarcoma protuberans (DFSP) is a fibrohistiocytic tumor of low grade malignant potential. Although rare, pediatric cases pose a particular challenge in diagnosis and management. In children, the clinical appearance may be heterogeneous and a high index of suspicion is necessary to avoid delays in diagnosis which can lead to further morbidity. Histologic examination, often with the use of appropriate immunostains, is necessary for diagnosis. Advances in the understanding of the molecular genetics of DFSP have led to further diagnostic and therapeutic modalities. DFSP is thought to result from a translocation between platelet‐derived growth factor beta (PDGFB, 22q13.1) and type 1 collagen (COL1A1, 17q21∼22) leading to a fusion protein (PDGFB) which stimulates the PDGF receptor. Detection of this translocation in tissue via PCR or fluorescence in situ hybridization (FISH) can be helpful in difficult cases. While surgery with wide local excision or Mohs micrographic surgery is the mainstay of treatment, the use of targeted therapy with imatanib mesylate shows promise in large or unresectable tumors. Knowledge of the clinical features, histology, genetics, and treatment options is important for successful management of these tumors.
- 11 July 2012
- Published by Wiley in Pediatric Dermatology
- Vol. 29 (6) , 707-713
Dermatofibrosarcoma Protuberans in Children: an Update on the Diagnosis and Treatment
Abstract: Dermatofibrosarcoma protuberans (DFSP) is a fibrohistiocytic tumor of low grade malignant potential. Although rare, pediatric cases pose a particular challenge in diagnosis and management. In children, the clinical appearance may be heterogeneous and a high index of suspicion is necessary to avoid delays in diagnosis which can lead to further morbidity. Histologic examination, often with the use of appropriate immunostains, is necessary for diagnosis. Advances in the understanding of the molecular genetics of DFSP have led to further diagnostic and therapeutic modalities. DFSP is thought to result from a translocation between platelet‐derived growth factor beta (PDGFB, 22q13.1) and type 1 collagen (COL1A1, 17q21∼22) leading to a fusion protein (PDGFB) which stimulates the PDGF receptor. Detection of this translocation in tissue via PCR or fluorescence in situ hybridization (FISH) can be helpful in difficult cases. While surgery with wide local excision or Mohs micrographic surgery is the mainstay of treatment, the use of targeted therapy with imatanib mesylate shows promise in large or unresectable tumors. Knowledge of the clinical features, histology, genetics, and treatment options is important for successful management of these tumors.
- 1 July 2012
- Vol. 11 (7) , 872-5
Effective topical combination therapy for treatment of lichen striatus in children: a case series and review.
Lichen striatus (LS) is an uncommon linear dermatosis that is primarily seen in children from 4 months to 15 years of age. While some of these eruptions are asymptomatic, others can be quite pruritic. In darker-skinned individuals, post-inflammatory hypopigmentation can be significant and may provide a cause for concern for the patients and/or their parents. In our case series of 4 patients, we observed rapid resolution of LS by combining a topical retinoid with a topical steroid. To our knowledge, this is the first report of successful treatment with this kind of combination therapy in the English literature. The patients not only achieved satisfying cosmesis, but also complete resolution of their pruritus. The most common side effect of topical tazarotene is localized irritation at treatment sites, but the patients in this particular series tolerated the treatment well.
- 1 July 2012
- Vol. 11 (7) , 872-5
Effective topical combination therapy for treatment of lichen striatus in children: a case series and review.
Lichen striatus (LS) is an uncommon linear dermatosis that is primarily seen in children from 4 months to 15 years of age. While some of these eruptions are asymptomatic, others can be quite pruritic. In darker-skinned individuals, post-inflammatory hypopigmentation can be significant and may provide a cause for concern for the patients and/or their parents. In our case series of 4 patients, we observed rapid resolution of LS by combining a topical retinoid with a topical steroid. To our knowledge, this is the first report of successful treatment with this kind of combination therapy in the English literature. The patients not only achieved satisfying cosmesis, but also complete resolution of their pruritus. The most common side effect of topical tazarotene is localized irritation at treatment sites, but the patients in this particular series tolerated the treatment well.
- 13 October 2011
- Published by Wiley in Pediatric Dermatology
- Vol. 29 (3) , 324-326
Treatment of Recalcitrant Excessive Granulation Tissue with Photodynamic Therapy in an Eight-Year-Old Patient with Focal Dermal Hypoplasia Syndrome
We report a pediatric patient with focal dermal hypoplasia syndrome who developed painful excessive granulation tissue refractory to traditional medical and surgical therapies. Complete response was achieved rapidly with a combination of photodynamic therapy and intralesional steroid injections. The patient has remained in remission for longer than a year.
- 13 October 2011
- Published by Wiley in Pediatric Dermatology
- Vol. 29 (3) , 324-326
Treatment of Recalcitrant Excessive Granulation Tissue with Photodynamic Therapy in an Eight-Year-Old Patient with Focal Dermal Hypoplasia Syndrome
We report a pediatric patient with focal dermal hypoplasia syndrome who developed painful excessive granulation tissue refractory to traditional medical and surgical therapies. Complete response was achieved rapidly with a combination of photodynamic therapy and intralesional steroid injections. The patient has remained in remission for longer than a year.
- 15 March 2011
- Published by Wiley in Pediatric Dermatology
- Vol. 28 (2) , 172-175
A Case of Sclerodermatous Graft‐versus‐Host Disease Responsive to Imatinib Therapy
Abstract: Sclerodermatous graft‐versus‐host disease (sGVHD) is a rare, late complication of hematopoietic cell transplantation. Classified as a variant of chronic graft‐versus‐host disease, sGVHD is thought to be predominantly an immune‐mediated response characterized by aberrant T‐cell function and dysregulation of tyrosine kinase cascades. Recently, the profibrotic cytokine transforming growth factor B and stimulatory autoantibodies against the platelet‐derived growth factor receptor have been implicated in the pathogenesis of sGVHD. Treatment of sGVHD remains disappointing and largely limited by systemic side effects. Imatinib mesylate is a small molecule tyrosine kinase inhibitor that has been shown to selectively inhibit both the platelet‐derived growth factor receptor and transforming growth factor‐β signaling pathways. We report a case of sGVHD in a pediatric patient that was resistant to traditional therapy but showed improvement in cutaneous symptoms following daily treatment with 400 mg of imatinib mesylate. Due to its favorable side‐effect profile, specificity for molecular pathways deranged in sGVHD and proven efficacy in other sclerodermoid diseases, imatinib mesylate is a promising new tool in the management of this challenging disease.
- 15 March 2011
- Published by Wiley in Pediatric Dermatology
- Vol. 28 (2) , 172-175
A Case of Sclerodermatous Graft‐versus‐Host Disease Responsive to Imatinib Therapy
Abstract: Sclerodermatous graft‐versus‐host disease (sGVHD) is a rare, late complication of hematopoietic cell transplantation. Classified as a variant of chronic graft‐versus‐host disease, sGVHD is thought to be predominantly an immune‐mediated response characterized by aberrant T‐cell function and dysregulation of tyrosine kinase cascades. Recently, the profibrotic cytokine transforming growth factor B and stimulatory autoantibodies against the platelet‐derived growth factor receptor have been implicated in the pathogenesis of sGVHD. Treatment of sGVHD remains disappointing and largely limited by systemic side effects. Imatinib mesylate is a small molecule tyrosine kinase inhibitor that has been shown to selectively inhibit both the platelet‐derived growth factor receptor and transforming growth factor‐β signaling pathways. We report a case of sGVHD in a pediatric patient that was resistant to traditional therapy but showed improvement in cutaneous symptoms following daily treatment with 400 mg of imatinib mesylate. Due to its favorable side‐effect profile, specificity for molecular pathways deranged in sGVHD and proven efficacy in other sclerodermoid diseases, imatinib mesylate is a promising new tool in the management of this challenging disease.
- Open Access
- 1 August 2010
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 146 (8) , 877-881
Lipoatrophic Panniculitis
Case Report from JAMA Dermatology — Lipoatrophic Panniculitis — Case Report and Review of the Literature
- 1 August 2010
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 146 (8) , 877-881
Open AccessLipoatrophic Panniculitis
Case Report from JAMA Dermatology — Lipoatrophic Panniculitis — Case Report and Review of the Literature
- Open Access
- 1 July 2010
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 146 (7) , 715-718
Topical Rapamycin
Case Report from JAMA Dermatology — Topical Rapamycin — A Novel Approach to Facial Angiofibromas in Tuberous Sclerosis
- 1 July 2010
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 146 (7) , 715-718
Open AccessTopical Rapamycin
Case Report from JAMA Dermatology — Topical Rapamycin — A Novel Approach to Facial Angiofibromas in Tuberous Sclerosis
- 1 April 2010
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 36 (4) , 546-550
Mohs Surgical Excision of a Granular Cell Tumor with Plexiform Features on the Arm of a 7-Year-Old Child
- 1 April 2010
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 36 (4) , 546-550
Mohs Surgical Excision of a Granular Cell Tumor with Plexiform Features on the Arm of a 7-Year-Old Child